MX2024000145A - Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva. - Google Patents
Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva.Info
- Publication number
- MX2024000145A MX2024000145A MX2024000145A MX2024000145A MX2024000145A MX 2024000145 A MX2024000145 A MX 2024000145A MX 2024000145 A MX2024000145 A MX 2024000145A MX 2024000145 A MX2024000145 A MX 2024000145A MX 2024000145 A MX2024000145 A MX 2024000145A
- Authority
- MX
- Mexico
- Prior art keywords
- atp
- methods
- cognitive function
- compositions containing
- adenosine triphosphate
- Prior art date
Links
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title abstract 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 title 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 abstract 2
- 229960001456 adenosine triphosphate Drugs 0.000 abstract 2
- 230000036997 mental performance Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
- 230000035484 reaction time Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213378P | 2021-06-22 | 2021-06-22 | |
| PCT/US2022/034510 WO2022271813A1 (en) | 2021-06-22 | 2022-06-22 | Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000145A true MX2024000145A (es) | 2024-03-22 |
Family
ID=84544774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000145A MX2024000145A (es) | 2021-06-22 | 2022-06-22 | Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva. |
Country Status (12)
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000095695A (ja) * | 1998-07-23 | 2000-04-04 | Nippon Koutai Kenkyusho:Kk | 精神分裂病治療薬 |
| US20030069203A1 (en) * | 2001-06-04 | 2003-04-10 | Lee Steve S. | Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate |
| US7629329B2 (en) * | 2001-06-04 | 2009-12-08 | Tsi Health Sciences, Inc. | Method for increasing muscle mass and strength through administration of adenosine triphosphate |
| US20050261239A1 (en) * | 2004-05-23 | 2005-11-24 | Universiteit Van Maastricht | Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue |
| KR101424833B1 (ko) * | 2006-06-27 | 2014-08-01 | 코와 가부시키가이샤 | 피로 예방 및/또는 회복을 위한 의약 |
| US9522161B2 (en) * | 2010-10-26 | 2016-12-20 | Advanced Bio Development, Inc. | Performance enhancing composition and method of delivering nutrients |
| CN113142581B (zh) * | 2010-12-23 | 2025-07-22 | 阿马曾提斯公司 | 用于改善线粒体功能的组合物和方法 |
| US20140044690A1 (en) * | 2012-08-08 | 2014-02-13 | University Of South Florida | High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases |
| BR112015005199B1 (pt) * | 2012-09-10 | 2022-09-06 | Metabolic Technologies, Inc | Composição, e, método para fornecer um benefício a um animal em necessidade do mesmo |
| WO2014106860A2 (en) * | 2013-01-03 | 2014-07-10 | Laila Nutraceuticals | Synergistic dietary supplement compositions for enhancing physical performance and energy levels |
| US10888576B2 (en) * | 2018-10-08 | 2021-01-12 | Metabolic Technologies, Inc. | Composition of HMB and ATP and methods of use |
| WO2021046357A1 (en) * | 2019-09-05 | 2021-03-11 | Jiangyin Tsi Pharmaceutical Co., Ltd. | Compositions containing adenosine triphosphate (atp) and methods of use |
-
2022
- 2022-06-22 JP JP2023579443A patent/JP2024524288A/ja active Pending
- 2022-06-22 AU AU2022297444A patent/AU2022297444A1/en active Pending
- 2022-06-22 EP EP22829221.5A patent/EP4358972A4/en active Pending
- 2022-06-22 CN CN202280056829.6A patent/CN117835985A/zh active Pending
- 2022-06-22 US US18/573,609 patent/US20240299435A1/en active Pending
- 2022-06-22 PE PE2023003445A patent/PE20241617A1/es unknown
- 2022-06-22 MX MX2024000145A patent/MX2024000145A/es unknown
- 2022-06-22 CA CA3224861A patent/CA3224861A1/en active Pending
- 2022-06-22 WO PCT/US2022/034510 patent/WO2022271813A1/en not_active Ceased
-
2023
- 2023-12-22 CL CL2023003882A patent/CL2023003882A1/es unknown
-
2024
- 2024-01-19 EC ECSENADI20244256A patent/ECSP24004256A/es unknown
- 2024-01-22 CO CONC2024/0000517A patent/CO2024000517A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20241617A1 (es) | 2024-08-07 |
| CA3224861A1 (en) | 2022-12-29 |
| CN117835985A (zh) | 2024-04-05 |
| CO2024000517A2 (es) | 2024-05-10 |
| AU2022297444A1 (en) | 2024-01-18 |
| US20240299435A1 (en) | 2024-09-12 |
| EP4358972A4 (en) | 2025-04-16 |
| ECSP24004256A (es) | 2024-02-29 |
| EP4358972A1 (en) | 2024-05-01 |
| WO2022271813A1 (en) | 2022-12-29 |
| CL2023003882A1 (es) | 2024-07-05 |
| JP2024524288A (ja) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022553530A1 (en) | 1'-cyano nucleoside analogs and uses thereof | |
| Fournet et al. | Substituted quinolines induce inhibition of proliferation of HTLV-1 infected cells | |
| BR0108485A (pt) | Derivados do antiviral azaindol | |
| PT1539783E (pt) | Inibidores de nucleósido fosforilases e de nucleosidases | |
| CY1113354T1 (el) | Αναστολεις φωσφορυλασων και νουκλεοζιδασων νουκλεοζιδιου | |
| HUP0400314A2 (hu) | Gyógyszer-kombinációk rák kezelésére | |
| ES2172575T3 (es) | Composicion bactericida. | |
| NZ553405A (en) | Nucleoside phosphonate conjugates as anti-HIV agents | |
| ES457110A1 (es) | Un procedimiento para preparar catalizadores de planta modi-ficados. | |
| MA27427A1 (fr) | Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie | |
| HUP9803022A2 (hu) | Triazolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk | |
| EP4644394A3 (en) | Antiviral compounds | |
| HUP0001923A1 (hu) | Peszticid hatású 1-aril-3-imino-pirazolok, eljárás előállításukra és alkalmazásuk | |
| MX2024001590A (es) | Cianopiridina y degradadores de cianopirimidina bcl6. | |
| MX2022011844A (es) | Terapia combinada con un inhibidor de idh mutante. | |
| HUP9901858A2 (hu) | Eljárás adenilszukcinát-szintetáz aktivitásának gátlására metil-tio-adenozin-foszforilázban hiányos sejtekben | |
| BR9916849A (pt) | Análogos de nucleosìdeos antivirais | |
| CL2023003882A1 (es) | Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva | |
| ES2103577T3 (es) | Compuestos antiviricos de naftoquinona, composiciones que los contienen y utilizaciones de estos compuestos. | |
| WO2005023270A3 (en) | Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors | |
| JPS5649306A (en) | Weed beetle attractant composition | |
| GEAP202415952A (en) | Pyrimidine-based bicycles as antiviral agents for the treatment and prevention of hiv infection | |
| AR021577A1 (es) | Preparado con una amplitud terapeutica mejorada, que contiene inhibidores de la sintesis de los nucleotidos | |
| BR112022025480A2 (pt) | Composições e métodos para superar a resistência mediada por microambiente por meio de direcionamento de e-selectina | |
| Davies et al. | Durable graft‐versus‐leukaemia effects without donor lymphocyte infusions–results of a phase II study of sequential T‐replete allogeneic transplantation for high‐risk acute myeloid leukaemia and myelodysplasia |